Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk

Background: Experimental and epidemiologic evidence have suggested that chronic inflammation may play a critical role in endometrial carcinogenesis. Methods: To investigate this hypothesis, a two-stage study was carried out to evaluate single-nucleotide polymorphisms (SNP) in inflammatory pathway genes in association with endometrial cancer risk. In stage I, 64 candidate pathway genes were identified and 4,542 directly genotyped or imputed SNPs were analyzed among 832 endometrial cancer cases and 2,049 controls, using data from the Shanghai Endometrial Cancer Genetics Study. Linkage disequilibrium of stage I SNPs significantly associated with endometrial cancer (P < 0.05) indicated that the majority of associations could be linked to one of 24 distinct loci. One SNP from each of the 24 loci was then selected for follow-up genotyping. Of these, 21 SNPs were successfully designed and genotyped in stage II, which consisted of 10 additional studies including 6,604 endometrial cancer cases and 8,511 controls. Results: Five of the 21 SNPs had significant allelic odds ratios (ORs) and 95% confidence intervals (CI) as follows: FABP1, 0.92 (0.85–0.99); CXCL3, 1.16 (1.05–1.29); IL6, 1.08 (1.00–1.17); MSR1, 0.90 (0.82–0.98); and MMP9, 0.91 (0.87–0.97). Two of these polymorphisms were independently significant in the replication sample (rs352038 in CXCL3 and rs3918249 in MMP9). The association for the MMP9 polymorphism remained significant after Bonferroni correction and showed a significant association with endometrial cancer in both Asian- and European-ancestry samples. Conclusions: These findings lend support to the hypothesis that genetic polymorphisms in genes involved in the inflammatory pathway may contribute to genetic susceptibility to endometrial cancer. Impact statement: This study adds to the growing evidence that inflammation plays an important role in endometrial carcinogenesis. Cancer Epidemiol Biomarkers Prev; 22(2); 216–23. ©2012 AACR.

[1]  Bing Zhang,et al.  GLAD4U: deriving and prioritizing gene lists from PubMed literature , 2012, BMC Genomics.

[2]  M. Lappas.  Nuclear factor-κB mediates placental growth factor induced pro-labour mediators in human placenta. , 2012, Molecular human reproduction.

[3]  X. Wan,et al.  Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. , 2012, Oncology reports.

[4]  M. Beckmann,et al.  Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[5]  W. Jonat,et al.  Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[6]  Xiaoxia Zhu,et al.  Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts , 2011, PloS one.

[7]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[8]  M. Beckmann,et al.  Genome-wide association study identifies a common variant associated with risk of endometrial cancer , 2011, Nature Genetics.

[9]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[10]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[11]  A. Mueck,et al.  Hormonal contraception and risk of endometrial cancer: a systematic review. , 2010, Endocrine-related cancer.

[12]  G. Abecasis,et al.  MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes , 2010, Genetic epidemiology.

[13]  Michael Boehnke,et al.  LocusZoom: regional visualization of genome-wide association scan results , 2010, Bioinform..

[14]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[15]  I. Thompson,et al.  Single and Multivariate Associations of MSR1, ELAC2, and RNASEL with Prostate Cancer in an Ethnic Diverse Cohort of Men , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[16]  D. Choi,et al.  Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. , 2009, Gynecologic oncology.

[17]  N. Laird,et al.  Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women , 2009, International journal of cancer.

[18]  S. Lye,et al.  Gonadotropin-releasing hormone-regulated chemokine expression in human placentation. , 2009, American journal of physiology. Cell physiology.

[19]  Jack A. Taylor,et al.  SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies , 2009, Nucleic Acids Res..

[20]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[21]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[22]  Joshua M. Korn,et al.  Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs , 2008, Nature Genetics.

[23]  M. Stephens,et al.  High-Resolution Mapping of Expression-QTLs Yields Insight into Human Gene Regulation , 2008, PLoS genetics.

[24]  Jinbo Chen,et al.  MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. , 2007, Carcinogenesis.

[25]  S. Vacher,et al.  CXC chemokines located in the 4q21 region are up-regulated in breast cancer. , 2007, Endocrine-related cancer.

[26]  R. Ness,et al.  Inflammation and Endometrial Cancer: A Hypothesis , 2005, Cancer Epidemiology Biomarkers & Prevention.

[27]  J. Olsen,et al.  Relationship of Benign Gynecologic Diseases to Subsequent Risk of Ovarian and Uterine Tumors , 2005, Cancer Epidemiology Biomarkers & Prevention.

[28]  S. Bellone,et al.  High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. , 2005, Gynecologic oncology.

[29]  R. Khokha,et al.  Metalloproteinase inhibitor TIMP‐1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration , 2005, Hepatology.

[30]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[31]  B. Wisse,et al.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. , 2004, Journal of the American Society of Nephrology : JASN.

[32]  U. Puistola,et al.  Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. , 2004, Gynecologic oncology.

[33]  N. Sugino,et al.  Withdrawal of ovarian steroids stimulates prostaglandin F2alpha production through nuclear factor-kappaB activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. , 2004, The Journal of reproduction and development.

[34]  X. Shu,et al.  Menstrual and reproductive factors and endometrial cancer risk: Results from a population‐based case‐control study in urban Shanghai , 2004, International journal of cancer.

[35]  Paul Hardiman,et al.  Polycystic ovary syndrome and endometrial carcinoma , 2003, The Lancet.

[36]  K. Chang,et al.  Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three‐dimensional coculture , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[37]  J. Carpten,et al.  Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk , 2002, Nature Genetics.

[38]  Y. Hung,et al.  Survivin gene expression in endometriosis. , 2002, The Journal of clinical endocrinology and metabolism.

[39]  P. Ferrara,et al.  Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy)benzophenone. , 2002, Bioconjugate chemistry.

[40]  R.,et al.  Rapid Mobilization of Hematopoietic Progenitor Cells in Rhesus Monkeys by a Single Intravenous Injection of Interleukin-8 , 2002 .

[41]  S L Normand,et al.  Meta-analysis: formulating, evaluating, combining, and reporting. , 1999, Statistics in medicine.

[42]  S. Normand,et al.  TUTORIAL IN BIOSTATISTICS META-ANALYSIS : FORMULATING , EVALUATING , COMBINING , AND REPORTING , 1999 .

[43]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[44]  J. Schlesselman,et al.  Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. , 1997, Human reproduction.

[45]  L. Lipworth,et al.  A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. , 1996, Oncology.

[46]  T. Sellers,et al.  Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. , 1996, American journal of epidemiology.

[47]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[48]  S. Tabibzadeh.  Cytokines and the hypothalamic-pituitary-ovarian-endometrial axis. , 1994, Human reproduction.

[49]  R. Hoover,et al.  Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. , 1992, American journal of obstetrics and gynecology.

[50]  M. Pike,et al.  Increased cell division as a cause of human cancer. , 1990, Cancer research.

[51]  N. Risch,et al.  Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. , 1989, American journal of human genetics.

[52]  M. Pike,et al.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. , 1988, British Journal of Cancer.

[53]  M. Gangemi,et al.  Obesity as a risk factor for endometrial cancer. , 1987, Clinical and experimental obstetrics & gynecology.